| Aug 29 |
Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants
|
| Aug 27 |
Ensysce Biosciences Announces IRB Approval for Key MPAR Study
|
| Aug 27 |
Ensysce wins $14M federal grant for lead pain therapy
|
| Aug 27 |
Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection
|
| Aug 27 |
ENSC Treatment Gets Substantial Grant
|
| Aug 23 |
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)
|
| Aug 16 |
Ensysce Biosciences Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Aug 15 |
Ensysce Biosciences GAAP EPS of -$0.22 beats by $0.11
|
| Aug 15 |
ENSC Furthers Important Drug Research
|
| Aug 14 |
Ensysce Biosciences Reports Second Quarter 2024 Financial Results
|
